Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
CVS Health (NYSE:CVS) executives said the company is seeing improved momentum across its insurance, pharmacy, care delivery and balance-sheet priorities, while maintaining a cautious outlook on healthcare cost trends and several 2027 headwinds.
Speaking at an investor conference, Chief Financial Of
Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns.
Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 16.85% on an annualized basis producing an average annual return of 30.5%. Currently, Eli Lilly has a market capitalization of $1.00 trillion.
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
Stocks pulled back after a strong jobs report stoked rate-hike concerns. MarketBeat writers recap earnings-season themes, covering AI, cybersecurity, retail, energy, and dividend stocks.
FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.
